R.D. James

6.2k total citations · 3 hit papers
58 papers, 4.5k citations indexed

About

R.D. James is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, R.D. James has authored 58 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 30 papers in Surgery and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in R.D. James's work include Colorectal and Anal Carcinomas (28 papers), Colorectal Cancer Surgical Treatments (23 papers) and Colorectal Cancer Treatments and Studies (19 papers). R.D. James is often cited by papers focused on Colorectal and Anal Carcinomas (28 papers), Colorectal Cancer Surgical Treatments (23 papers) and Colorectal Cancer Treatments and Studies (19 papers). R.D. James collaborates with scholars based in United Kingdom, Australia and United States. R.D. James's co-authors include David Cunningham, Helen Meadows, C. Topham, P M Wilkinson, Patrice Herait, Hans Starkhammar, Lucile Awad, Christian Jacques, Tom Børge Johannesen and Cornelis J.A. Punt and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

R.D. James

56 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1998 973 citations David Cunningham, Seppo Pyrhönen et al. The Lancet profile →
Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin

1996 581 citations S.J. Arnott, David Cunningham et al. The Lancet profile →
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial

2013 459 citations R.D. James, Rob Glynne‐Jones et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R.D. James United Kingdom	27	2.9k	2.2k	1.6k	617	484	58	4.5k
Jorge Aparicio Spain	29	3.0k 1.0×	1.7k 0.8×	1.4k 0.9×	667 1.1×	639 1.3×	147	4.3k
Saul E. Rivkin United States	40	3.6k 1.2×	971 0.4×	2.0k 1.3×	815 1.3×	180 0.4×	127	5.8k
J. T. Hartmann Germany	25	2.4k 0.8×	1.2k 0.5×	2.0k 1.3×	600 1.0×	460 1.0×	59	3.8k
G. Ganem France	27	3.3k 1.1×	842 0.4×	1.1k 0.7×	1.1k 1.7×	993 2.1×	68	4.5k
Luigi Manzione Italy	29	2.4k 0.8×	637 0.3×	1.3k 0.8×	267 0.4×	350 0.7×	88	3.4k
Ninja Antonini Netherlands	27	2.4k 0.8×	1.5k 0.7×	927 0.6×	963 1.6×	527 1.1×	50	4.1k
Sergio Ricci Italy	25	2.7k 0.9×	1.9k 0.9×	1.2k 0.8×	559 0.9×	1.4k 2.8×	62	5.5k
Jean‐François Seitz France	38	4.2k 1.4×	2.8k 1.3×	2.1k 1.3×	582 0.9×	434 0.9×	130	5.9k
Giacomo Cartenì Italy	27	1.7k 0.6×	864 0.4×	1.4k 0.9×	213 0.3×	277 0.6×	110	3.2k
Stéphane Culine France	27	3.3k 1.1×	2.5k 1.1×	1.2k 0.8×	322 0.5×	89 0.2×	109	5.4k

Countries citing papers authored by R.D. James

Since Specialization

Citations

This map shows the geographic impact of R.D. James's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R.D. James with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R.D. James more than expected).

Fields of papers citing papers by R.D. James

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R.D. James. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R.D. James. The network helps show where R.D. James may publish in the future.

Co-authorship network of co-authors of R.D. James

This figure shows the co-authorship network connecting the top 25 collaborators of R.D. James. A scholar is included among the top collaborators of R.D. James based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R.D. James. R.D. James is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

James, R.D., Sandro Barni, Ludwig Fischer von Weikersthal, et al.. (2010). Improving chemotherapy capacity by switching from i.v. to oral vinorelbine. University of Southern Denmark Research Portal (University of Southern Denmark). 4. 14–18. 5 indexed citations

Glynne‐Jones, Rob, David Sebag‐Montefiore, Richard Adams, et al.. (2010). “Mind the Gap”—The Impact of Variations in the Duration of the Treatment Gap and Overall Treatment Time in the First UK Anal Cancer Trial (ACT I). International Journal of Radiation Oncology*Biology*Physics. 81(5). 1488–1494. 40 indexed citations

James, R.D., Sandro Barni, Vittorio Gebbia, et al.. (2009). 3612 Improving chemotherapy capacity by switching from intravenous to oral vinorelbine: TAMINO, an international time and motion audit. European Journal of Cancer Supplements. 7(2). 211–212. 2 indexed citations

Welch, Richard, R.D. James, P. M. Wilkinson, Filiberto Belli, & Richard Cowan. (2006). Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer.. PubMed. 1(4). 261–6. 12 indexed citations

James, R.D., N. Botwood, C. C. Vernon, & P. Price. (2003). Raltitrexed plus radiotherapy for the treatment of unresectable/recurrent rectal cancer: A phase I study. Annals of Oncology. 14(4). 570–573. 5 indexed citations

Cunningham, David & R.D. James. (2001). Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer. European Journal of Cancer. 37(7). 826–834. 17 indexed citations

James, R.D., David Kerr, JA Ledermann, et al.. (2000). Excess treatment related deaths and impaired quality of life show raltitrexed is inferior to infusional 5FU regimens in the palliative chemotherapy of advanced colorectal cancer (CRC): Final results of MRC CR06. UCL Discovery (University College London). 17 indexed citations

James, R.D., P. Price, & Vincenzo Valentini. (1999). Raltitrexed (Tomudex™) concomitant with radiotherapy as adjuvant treatment for patients with rectal cancer: preliminary results of phase I studies. European Journal of Cancer. 35. S19–S22. 13 indexed citations

Cunningham, David, Seppo Pyrhönen, R.D. James, et al.. (1998). Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. The Lancet. 352(9138). 1413–1418. 973 indexed citations breakdown →

10.

Millward, Michael, John Zalcberg, James F. Bishop, et al.. (1997). Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.. Journal of Clinical Oncology. 15(2). 750–758. 69 indexed citations

11.

Arnott, S.J., David Cunningham, James Gallagher, et al.. (1996). Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. The Lancet. 348. 1049–1054. 581 indexed citations breakdown →

12.

Cooper, Rachel, et al.. (1996). Cardiac perforation associated with continuous infusional chemotherapy. Clinical Oncology. 8(6). 404–405. 1 indexed citations

13.

Radford, John, D Crowther, A. Z. S. Rohatiner, et al.. (1995). Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease.. Journal of Clinical Oncology. 13(9). 2379–2385. 35 indexed citations

14.

Marsh, P J, R.D. James, & P. F. Schofield. (1994). Adjuvant preoperative radiotherapy for locally advanced rectal carcinoma. Diseases of the Colon & Rectum. 37(12). 1205–1214. 191 indexed citations

15.

Wilson, Malcolm, et al.. (1994). An evaluation of five different methods for estimating proliferation in human colorectal adenocarcinomas. Surgical Oncology. 3(5). 263–273. 9 indexed citations

16.

Pettengell, Ruth, Howard Gurney, John Radford, et al.. (1992). Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood. 80(6). 1430–1436. 328 indexed citations

17.

James, R.D., P M Wilkinson, Filiberto Belli, Richard Welch, & Richard Cowan. (1992). Recombinant Human Erythropoietin in Patients with Ovarian Carcinoma and Anaemia Secondary to Cisplatin and Carboplatin Chemotherapy: Preliminary Results. Acta Haematologica. 87(1). 12–15. 26 indexed citations

18.

James, R.D., et al.. (1992). Clinical magnetic resonance: Imaging and spectroscopy. Clinical Imaging. 16(1). 62–63. 1 indexed citations

19.

James, R.D., et al.. (1991). Prognostic factors in colorectal carcinoma treated by preoperative radiotherapy and immediate surgery. Diseases of the Colon & Rectum. 34(7). 546–551. 27 indexed citations

20.

James, R.D. & P F Schofield. (1989). The value of radiotherapy for rectal cancer. Baillière s Clinical Gastroenterology. 3(3). 647–669. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact